financetom
Business
financetom
/
Business
/
--Robinhood Markets Q2 Transaction-Based Options Revenue at $182 Million vs Visible Alpha Analyst Consensus of $165.4 Million; Crypto Revenue at $81 Million vs Consensus of $85 Million
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--Robinhood Markets Q2 Transaction-Based Options Revenue at $182 Million vs Visible Alpha Analyst Consensus of $165.4 Million; Crypto Revenue at $81 Million vs Consensus of $85 Million
Aug 7, 2024 1:25 PM

04:11 PM EDT, 08/07/2024 (MT Newswires) --

Price: 17.10, Change: -0.02, Percent Change: -0.12

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BWR Exploration Signs LOI for Business Combination With Electro Metal
BWR Exploration Signs LOI for Business Combination With Electro Metal
Dec 27, 2024
11:33 AM EST, 12/27/2024 (MT Newswires) -- BWR Exploration (BWR.V) on Friday said it has signed a binding Letter of Intent with privately-held Electro Metals and Mining that would result in the reverse takeover of BWR by Electro. Toronto-based Electro owns a block of claims covering 113.6 hectares with historical mineralization and, on an adjacent block of 5,830 hectares, Electro...
What's Going On With SEALSQ Stock Friday?
What's Going On With SEALSQ Stock Friday?
Dec 27, 2024
SEALSQ Corp. ( LAES )  shares are moving amid volatility on Friday. The stock fell briefly after the market opened only to rebound as the day continued, On Thursday evening, the company announced that Nasdaq had confirmed it regained compliance with the minimum bid price rules. The Details: The company was given until Jan. 28 by the Nasdaq to regain...
US FDA approves injectable form of Bristol Myers' Opdivo
US FDA approves injectable form of Bristol Myers' Opdivo
Dec 27, 2024
(Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ( BMY ) blockbuster cancer drug, Opdivo. Opdivo is part of a class of drugs called PD-1 inhibitors, which enhance the immune system's ability to fight cancer by removing its natural brakes. Like other PD-1 drugs such as Merck's...
--Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, Appeals Court Rules
--Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, Appeals Court Rules
Dec 27, 2024
11:47 AM EST, 12/27/2024 (MT Newswires) -- Price: 98.46, Change: +0.06, Percent Change: +0.06 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved